JPWO2020167376A5 - - Google Patents

Info

Publication number

JPWO2020167376A5

JPWO2020167376A5 JP2021547075A JP2021547075A JPWO2020167376A5 JP WO2020167376 A5 JPWO2020167376 A5 JP WO2020167376A5 JP 2021547075 A JP2021547075 A JP 2021547075A JP 2021547075 A JP2021547075 A JP 2021547075A JP WO2020167376 A5 JPWO2020167376 A5 JP WO2020167376A5

Authority

JP

Japan

Prior art keywords

antibody

seq

light chain

combination

amino acid

Prior art date

2022-12-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims description 117
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 109
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 95
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 95
• 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 60
• 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 claims description 28
• 239000000203 mixture Substances 0.000 claims description 24
• 238000002659 cell therapy Methods 0.000 claims description 17
• 210000004180 plasmocyte Anatomy 0.000 claims description 17
• 229960002204 daratumumab Drugs 0.000 claims description 13
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 10
• 230000006872 improvement Effects 0.000 claims description 10
• 208000023761 AL amyloidosis Diseases 0.000 claims description 8
• 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims description 8
• 208000021161 Plasma cell disease Diseases 0.000 claims description 8
• 229960001467 bortezomib Drugs 0.000 claims description 8
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 8
• 230000036541 health Effects 0.000 claims description 8
• 230000006842 hematologic response Effects 0.000 claims description 7
• 230000009467 reduction Effects 0.000 claims description 7
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 5
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
• 108060003951 Immunoglobulin Proteins 0.000 claims description 5
• 229960002438 carfilzomib Drugs 0.000 claims description 5
• 108010021331 carfilzomib Proteins 0.000 claims description 5
• BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 5
• 229960004397 cyclophosphamide Drugs 0.000 claims description 5
• 229960003957 dexamethasone Drugs 0.000 claims description 5
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 5
• 229960004679 doxorubicin Drugs 0.000 claims description 5
• 229960003722 doxycycline Drugs 0.000 claims description 5
• XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 5
• 102000018358 immunoglobulin Human genes 0.000 claims description 5
• 229960003648 ixazomib Drugs 0.000 claims description 5
• MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 5
• 229960004942 lenalidomide Drugs 0.000 claims description 5
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 5
• 229960001924 melphalan Drugs 0.000 claims description 5
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 5
• 229960000688 pomalidomide Drugs 0.000 claims description 5
• UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 5
• 229960004618 prednisone Drugs 0.000 claims description 5
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 5
• 230000004044 response Effects 0.000 claims description 5
• 229960003433 thalidomide Drugs 0.000 claims description 5
• 229960001183 venetoclax Drugs 0.000 claims description 5
• LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
• 230000000295 complement effect Effects 0.000 claims description 4
• 230000004217 heart function Effects 0.000 claims description 4
• 229950007752 isatuximab Drugs 0.000 claims description 4
• 102000054727 Serum Amyloid A Human genes 0.000 claims description 3
• 108700028909 Serum Amyloid A Proteins 0.000 claims description 3
• 238000001990 intravenous administration Methods 0.000 claims description 3
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
• 230000006641 stabilisation Effects 0.000 claims description 3
• 238000011105 stabilization Methods 0.000 claims description 3
• 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 2
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 2
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 2
• 208000034578 Multiple myelomas Diseases 0.000 claims description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
• 208000007452 Plasmacytoma Diseases 0.000 claims description 2
• 230000000747 cardiac effect Effects 0.000 claims description 2
• 238000001802 infusion Methods 0.000 claims description 2
• 208000032839 leukemia Diseases 0.000 claims description 2
• 208000010721 smoldering plasma cell myeloma Diseases 0.000 claims description 2
• 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
• 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
• 238000002648 combination therapy Methods 0.000 description 10
• 238000009472 formulation Methods 0.000 description 4
• 230000000087 stabilizing effect Effects 0.000 description 4
• HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
• 229920001213 Polysorbate 20 Polymers 0.000 description 2
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
• 229940068977 polysorbate 20 Drugs 0.000 description 2
• 230000000694 effects Effects 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1